What is Geneyx Analysis?

To help physicians make decisions on which treatments are most effective, Geneyx has developed an AI-based bioinformatics platform called Geneyx Analysis. It combines a variety of hospital-based clinical genetic data into a single, highly accurate report. This technology helps physicians turn whole genome sequencing data into accurate diagnoses, and reduces the turnaround time from days to minutes. The company's advanced bioinformatics platform also allows researchers to more effectively leverage whole genome sequencing data.

The Geneyx platform offers new capabilities that help researchers leverage whole-genome sequencing data and distill novel findings that will lead to the development of personalized and targeted therapies. Today, much of the genetic data generated in hospitals around the world is stored in silos, making it difficult for pharmaceutical companies to integrate this data with real-time clinical evidence. Geneyx technology fills this gap and allows for better diagnostics and personalized treatments. Because the Geneyx platform leverages AI, it is helping researchers accelerate the development of targeted therapeutics.

The company's genetics platform offers a seamless pipeline from fastq files to VCF, and advanced data management and analysis software. Geneyx also incorporates the Weizmann Institute of Science's GeneCards knowledge suite. This combination of technology makes Geneyx a highly effective tool for pharmaceutical research groups. With this, they can more efficiently analyze complex diseases and improve patient care. Its cloud-based genetics platform also helps researchers conduct advanced gene-expression analysis.

The Geneyx platform helps hospitals and medical labs make better decisions about patient care by enabling clinical decision support for clinicians. In addition to offering the gold standard in unified global knowledge bases, the platform streamlines, automates, and simplifies workflow. In addition, Geneyx reduces clinical providers' liability and overhead costs through automation. With the help of Geneyx, physicians can more effectively use the vast amounts of data generated by whole genome sequencing.

Accenture has made a strategic investment in Israeli genomics company Geneyx Genomex Ltd. The company aims to improve patient outcomes associated with rare and hereditary diseases by leveraging genetic data. In addition to this, the company hopes to leverage Accenture's data of 55 million de-identified patient electronic medical records. The company's success may indicate the future of genetic data in medicine. So what do Accenture and Geneyx Genomex have in common?